Is Lipo-C approved or legal?

Lipo-C is not an FDA-approved drug. It is a compounded injection prepared by pharmacies, and its ingredients (methionine, inositol, choline, B12) are sold as supplements. Availability and legality depend on a prescriber and a licensed compounding pharmacy in your jurisdiction. This profile is research/educational only, not medical or legal advice.

What is the half-life and how often is it dosed?

There is no defined pharmacokinetic half-life for the Lipo-C blend; its nutrients are cleared by normal metabolic and renal pathways over hours. There is no established clinical dosing. Anecdotally, clinics and forum users report anywhere from twice-weekly to daily injections, but concentrations vary by compounder, so these are not standardized and are listed only as research reference.

Does Lipo-C actually cause weight loss?

There is no high-quality clinical evidence that the MIC injection causes meaningful weight loss on its own. Reported results generally occur alongside diet and exercise. The individual ingredients have legitimate metabolic roles, but that does not translate into proven injection-driven fat loss.

It is administered by injection, usually intramuscular or subcutaneous. Community reports describe abdominal subcutaneous, quadriceps, or shallow gluteal injections, sometimes with local lumps or a B-vitamin odor.

In healthy adults it is generally considered low-risk, with mostly local side effects (injection-site pain, lumps, B-vitamin body odor) and possible GI upset from high choline. However, it is a non-FDA-approved compounded product with limited safety data; people with kidney/liver disease, pregnancy, or relevant allergies should avoid it without medical supervision.

Aesthetic

Lipo-C

Also known as: Lipotropic injection, MIC, MIC injection, Lipotropic shot, Skinny shot

Compounded lipotropic (MIC) injection of methionine, inositol and choline marketed for fat metabolism; weak weight-loss evidence.

Last updated July 11, 2026

Buy Lipo-C

Overview

Lipo-C is a compounded "lipotropic" injection built around the MIC trio: methionine (an essential amino acid), inositol (a sugar alcohol / B-vitamin-like compound) and choline (an essential nutrient). Many formulations add vitamin B12 and sometimes L-carnitine or B-complex vitamins. It is typically offered by med-spas and weight-management clinics as an adjunct to diet and exercise rather than a standalone treatment. The term "lipotropic" refers to nutrients that help mobilize or metabolize fat in the liver. Choline and methionine have a genuinely well-established biochemical role in hepatic fat handling, and inositol has clinical data for insulin sensitivity in PCOS. However, evidence that injecting these nutrients into already well-nourished people produces meaningful fat loss is weak. Lipo-C is not an FDA-approved drug; it is a compounded preparation, and its components are sold as supplements. Marketing often overstates benefits. The honest picture is that the individual ingredients have plausible and in some cases proven roles in specific deficiency or disease states, but high-quality trials of the MIC injection itself for weight loss are essentially absent. This profile is provided for research and educational reference only and is not medical advice or an endorsement for human consumption.

How it works

Each component has a distinct, biochemically grounded role. Choline and methionine are lipotropic factors required for hepatic synthesis of phosphatidylcholine and very-low-density lipoprotein (VLDL), which exports triglycerides from the liver; deficiency of choline reliably causes hepatic fat accumulation (steatosis) in both animal models and humans on parenteral nutrition. Methionine is a methyl donor feeding the one-carbon/homocysteine cycle and is a precursor to S-adenosylmethionine. Inositol (chiefly myo-inositol) acts as a second-messenger precursor that improves insulin signaling. The combined rationale is that supplying these substrates supports fat transport out of the liver and overall energy metabolism. The unproven leap is that supplementing people who are not deficient in these nutrients translates into clinically meaningful systemic fat loss; the mechanism is best described as supportive/permissive rather than fat-burning.

Researched effects

Clinical Choline corrects and reverses hepatic steatosis (fatty liver) caused by choline deficiency
Clinical Myo-inositol improves insulin sensitivity markers (fasting insulin, HOMA-IR) in women with PCOS
Clinical Effects of myo-inositol on body weight and BMI are small and inconsistent across PCOS meta-analyses, with some finding no significant change
Preclinical Choline and methionine support hepatic VLDL/triglyceride export and reduce liver fat
Anecdotal Users report increased energy and improved mood (often attributed to added B12)
Anecdotal Modest weight/fat loss when paired with a structured diet and exercise program
Anecdotal MIC injection alone produces clinically significant weight loss independent of diet

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

No established clinical dosing in humans for the MIC injection as a fat-loss therapy; it is not FDA-approved and there are no randomized controlled trials of the combined injection. Evidence exists only for individual components in specific contexts (e.g. oral myo-inositol commonly studied at ~2-4 g/day in PCOS trials; choline adequate intake ~425-550 mg/day; choline repletion used to reverse parenteral-nutrition-associated steatosis).

Community-reported dosing (anecdotal)

Anecdotal and research-reference only, not medical advice. On forums such as ExcelMale and peptide communities, users report compounded Lipo-C protocols ranging widely from about 1 mL twice weekly up to 1 mL daily, with some clinics suggesting up to ~3 mL per injection. Reported injection sites include subcutaneous abdominal fat, quadriceps, or shallow intramuscular gluteal. Community reports note a strong B-vitamin odor at the injection site, and painful lumps when larger volumes are given subcutaneously. Concentrations vary by compounder, so volume-based dosing is not standardized.

Half-life: Unknown for the injectable blend; individual nutrients (methionine, inositol, choline, B12) are handled by normal metabolic and renal pathways over hours, but no defined pharmacokinetic half-life exists for Lipo-C as a product.
Routes: intramuscular, subcutaneous

Safety & side effects

Generally considered low-risk in healthy adults, but it is a compounded, non-FDA-approved product with variable quality and limited safety data. Reported issues are mostly local: injection-site pain, redness, lumps (especially with larger subcutaneous volumes), and a notable body/urine B-vitamin odor. High choline intake can cause GI upset, sweating, a fishy body odor and, at very high doses, low blood pressure. People with kidney or liver disease, those who are pregnant or breastfeeding, and anyone with relevant allergies should avoid use without medical supervision. The most important caution is expectation management: do not rely on it as a primary obesity treatment, and weigh it against far better-evidenced options.

Research summary

The clinical literature on the MIC/Lipo-C injection as a weight-loss therapy is essentially empty: there are no randomized controlled trials showing it produces clinically significant fat loss independent of diet and exercise, and it is not FDA-approved for this use. What exists is evidence for the individual ingredients, often in oral form and in specific populations. Choline deficiency is a long-established cause of hepatic steatosis, and repletion reverses it; this is robust biochemistry but applies to deficiency states, not to enhancing fat loss in well-nourished people. Methionine and choline have strong preclinical support as lipotropes that enable VLDL-mediated triglyceride export from the liver. Inositol has the strongest stand-alone clinical signal: meta-analyses of randomized trials show myo-inositol improves insulin sensitivity (fasting insulin, HOMA-IR) in women with PCOS, with only modest and inconsistent effects on body weight and BMI. None of this directly validates the injectable MIC blend for general weight loss. Taken together, Lipo-C sits in a low-evidence, heavily-marketed category. The honest synthesis is that its components have legitimate metabolic roles and a favorable basic-science rationale, but the leap from that rationale to meaningful, injection-driven fat loss in healthy or overweight individuals is unsupported by high-quality human trials. Community use is widespread and largely benign, with benefits that are plausibly attributable to concurrent lifestyle changes and added B12. This entry is research-use-only and is not a recommendation for human consumption.

FAQ

Is Lipo-C approved or legal?: Lipo-C is not an FDA-approved drug. It is a compounded injection prepared by pharmacies, and its ingredients (methionine, inositol, choline, B12) are sold as supplements. Availability and legality depend on a prescriber and a licensed compounding pharmacy in your jurisdiction. This profile is research/educational only, not medical or legal advice.
What is the half-life and how often is it dosed?: There is no defined pharmacokinetic half-life for the Lipo-C blend; its nutrients are cleared by normal metabolic and renal pathways over hours. There is no established clinical dosing. Anecdotally, clinics and forum users report anywhere from twice-weekly to daily injections, but concentrations vary by compounder, so these are not standardized and are listed only as research reference.
Does Lipo-C actually cause weight loss?: There is no high-quality clinical evidence that the MIC injection causes meaningful weight loss on its own. Reported results generally occur alongside diet and exercise. The individual ingredients have legitimate metabolic roles, but that does not translate into proven injection-driven fat loss.
How is Lipo-C given?: It is administered by injection, usually intramuscular or subcutaneous. Community reports describe abdominal subcutaneous, quadriceps, or shallow gluteal injections, sometimes with local lumps or a B-vitamin odor.
Is Lipo-C safe?: In healthy adults it is generally considered low-risk, with mostly local side effects (injection-site pain, lumps, B-vitamin body odor) and possible GI upset from high choline. However, it is a non-FDA-approved compounded product with limited safety data; people with kidney/liver disease, pregnancy, or relevant allergies should avoid it without medical supervision.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.